Zobrazeno 1 - 10
of 157
pro vyhledávání: '"Elaine C Siegfried"'
Autor:
Elaine C. Siegfried, Eric L. Simpson, Michael J. Cork, Peter D. Arkwright, Lara Wine Lee, Zhen Chen, Randy Prescilla, Ashish Bansal, Noah A. Levit, Ainara Rodríguez Marco
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 9, Pp 1987-2000 (2023)
Abstract Introduction Atopic dermatitis (AD) is heterogeneous in distribution pattern and clinical features. This analysis assessed the effect of dupilumab on the extent and severity of AD across various signs (erythema, edema/papulation, excoriation
Externí odkaz:
https://doaj.org/article/7f9dd1149078422ab5b7d8705d2ca580
Publikováno v:
JID Innovations, Vol 1, Iss 3, Pp 100019- (2021)
The beginning of the end (BOTE) sign has been proposed to describe well-recognized clinical signs of inflammation (including erythema, induration, and scale) that predict imminent resolution of molluscum contagiosum (MC). This phenomenon has never be
Externí odkaz:
https://doaj.org/article/22c04940d7e74414af2568b6262f611a
Autor:
Amy S Paller, Eric L Simpson, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Peter D Arkwright, Weily Soong, Mercedes E Gonzalez, Lynda C Schneider, Robert Sidbury, Benjamin Lockshin, Steven Meltzer, Zhixiao Wang, Leda P Mannent, Nikhil Amin, Yiping Sun, Elizabeth Laws, Bolanle Akinlade, Myles Dillon, Matthew P Kosloski, Mohamed A Kamal, Ariane Dubost-Brama, Naimish Patel, David M Weinreich, George D Yancopoulos, John T O’Malley, Ashish Bansal, Amber Pepper, David Cohen, David Pariser, Jeffrey Leflein, Jeffrey Weinberg, John Browning, Joyce Teng, Lara Wine Lee, Lawrence Sher, Lucia Diaz, Lynda Schneider, Ned Rupp, Peck Ong, Robert Cartwright, Andreas Pinter, Christina Schnopp, Anna Korkosz, Dorota Bystrzanowska, Ewa Sygula, Jacek Zdybski, Kamila Padlewska
Publikováno v:
The Lancet. 400:908-919
Current systemic treatments for children younger than 6 years with moderate-to-severe atopic dermatitis that is uncontrolled with topical therapies might have suboptimal efficacy and safety. Dupilumab is approved for older children and adults with at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d45214d2134d389bfe62af4219892e0
https://doi.org/10.1016/s0140-6736(22)01539-2
https://doi.org/10.1016/s0140-6736(22)01539-2
Publikováno v:
Dermatologic Clinics. 40:137-143
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in children. Standard-of-care treatment has been topical therapy. Oral corticosteroids are also commonly used to treat intermittent flares, despite guidelines that recommend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbe0c9350986fedffddd99d353480254
https://doi.org/10.1016/j.det.2021.12.002
https://doi.org/10.1016/j.det.2021.12.002
Autor:
Amy S. Paller, Lisa A. Beck, Andrew Blauvelt, Elaine C. Siegfried, Michael J. Cork, Andreas Wollenberg, Zhen Chen, Faisal A. Khokhar, Jignesh Vakil, Annie Zhang, Ashish Bansal, Sonya L. Cyr
Publikováno v:
Pediatric Dermatology. 39:187-196
Patients with moderate-to-severe atopic dermatitis (AD) have increased risk of cutaneous and extracutaneous infections. Dupilumab has previously been associated with reduced risk of serious/severe infections and non-herpetic skin infections in adults
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::976d9e3141da7ce832a7e6029d4de6be
https://doi.org/10.1111/pde.14909
https://doi.org/10.1111/pde.14909
Autor:
Elaine C Siegfried, Lara Wine Lee, Jonathan M Spergel, Sumeet Uppal, Anna Coleman, Brad Shumel, Randy Prescilla, Ashish Bansal, Sonya L Cyr
Publikováno v:
British Journal of Dermatology. 188
In patients with atopic dermatitis (AD), it is unknown whether suppression of dysregulated type 2 immune cytokines, interleukin-4 and interleukin-13, with dupilumab impacts the risk of viral infections following live attenuated vaccination. Current m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73cbf17745a0819e18734d0b2779fe4c
https://doi.org/10.1093/bjd/ljac140.036
https://doi.org/10.1093/bjd/ljac140.036
Publikováno v:
British Journal of Dermatology. 188
Continuous use of several traditional systemic atopic dermatitis (AD) treatments in pediatric patients is not recommended due to safety concerns and lack of long-term efficacy data. Children aged 6 months to 5 years with moderate-to-severe AD who had
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50fc5991b146eea93393df3ff2998eec
https://doi.org/10.1093/bjd/ljac140.030
https://doi.org/10.1093/bjd/ljac140.030
Autor:
Elaine C Siegfried, Michael J Cork, Peter D Arkwright, Andreas Wollenberg, Lawrence F Eichenfield, Michele Ramien, Faisal A Khokhar, Zhen Chen, Annie Zhang, Sonya L Cyr
Publikováno v:
British Journal of Dermatology. 188
Patients with atopic dermatitis (AD) have an increased risk of infection, including skin infections. Previous studies in children aged 6–11 years and adolescents showed that dupilumab is not associated with an increased risk of overall infections a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22015b6f0633316b4a7fec93552aa098
https://doi.org/10.1093/bjd/ljac140.031
https://doi.org/10.1093/bjd/ljac140.031
Autor:
Amy S Paller, Andreas Wollenberg, Elaine C Siegfried, Mercedes E Gonzalez, Benjamin Lockshin, Faisal A Khokhar, Zhen Chen, Tayler Gonzalez, Randy Prescilla
Publikováno v:
British Journal of Dermatology. 188
Many systemic therapies used for moderate-to-severe atopic dermatitis (AD) have immunosuppressive properties and necessitate laboratory screening and monitoring, adding to the treatment burden. Previous dupilumab studies in adults, adolescents and ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5b18f8c51db74f333c1c7cf7ed45a41
https://doi.org/10.1093/bjd/ljac140.032
https://doi.org/10.1093/bjd/ljac140.032
Autor:
Amy S. Paller, Elaine C. Siegfried, Michael J. Cork, Andreas Wollenberg, Peter D. Arkwright, Mercedes E. Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A. Levit, Randy Prescilla
Publikováno v:
Arkwright, P 2023, ' Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis ', Pediatric Drugs . https://doi.org/10.1007/s40272-022-00553-8
Background and ObjectivePrevious studies of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents, and severe atopic dermatitis in children aged 6 to < 12 years demonstrate no clinically important changes in la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0aafdd51fcb5f43b3726d128ab1ad54
https://research.manchester.ac.uk/en/publications/18e6b645-b1eb-4e1b-a228-cdaeca3c04b3
https://research.manchester.ac.uk/en/publications/18e6b645-b1eb-4e1b-a228-cdaeca3c04b3
